Shares of Imv Inc (NYSE:IMV) have been assigned an average broker rating score of 1.58 (Buy) from the four analysts that cover the stock, One equities research analyst has rated the stock with a hold recommendation, one has issued a buy recommendation and two have issued a strong buy recommendation on the company. IMV’s rating score has declined by 10.5% from three months ago as a result of various analysts’ upgrades and downgrades.
Analysts have set a twelve-month consensus price target of $10.31 for the company and are expecting that the company will post ($0.09) quarter, assigned IMV an industry rank of 87 related companies.
Get IMV alerts: Separately, Raymond James set a $10.00 price objective on IMV and gave the stock an “outperform” rating in a report on Friday, December 14th.
Hedge funds and other institutional investors have recently bought and sold shares of the business. FIL Ltd grew its stake in IMV by 0.9% during the 3rd quarter. FIL Ltd now owns 2,700,000 shares of the company’s stock valued at $15,845,000 after acquiring an additional 25,000 shares in the last quarter. First Manhattan Co. purchased a new position in IMV during the 3rd quarter valued at about $522,000. Renaissance Technologies LLC purchased a new position in IMV during the 2nd quarter valued at about $230,000. Prentiss Smith & Co. Inc. grew its stake in IMV by 1,929.0% during the 3rd quarter. Prentiss Smith & Co. Inc. now owns 44,374 shares of the company’s stock valued at $264,000 after acquiring an additional 42,187 shares in the last quarter. Finally, Ipswich Investment Management Co. Inc. purchased a new position in IMV during the 4th quarter valued at about $34,000.
IMV stock traded down $0.10 during midday trading on Wednesday, hitting $5.74. The company’s stock had a trading volume of 1,700 shares, compared to its average volume of 1,545. IMV has a 12 month low of $4.40 and a 12 month high of $7.21.
IMV (NYSE:IMV) last issued its quarterly earnings results on Friday, November 2nd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.05 million.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Recommended Story: What are Bollinger Bands?
IMV (IMV)
